Pharmaceutical giant Merck has announced the start of the Phase III Shorespan-007 trial to evaluate bomedemstat (MK-3543) in approximately 300 essential thrombocythemia (ET) patients globally. The study is set to compare bomedemstat to hydroxyurea, the current standard-of-care; and the FDA has granted bomedemstat both the ‘orphan drug’ and ‘fast track’ designations for ET and myelofibrosis treatment. This Phase III trial, along with the ongoing Shorespan-006 study, aims to advance bomedemstat as a novel treatment option for patients living with this challenging myeloproliferative neoplasm.

At OxyDial, we’re encouraged by Merck’s progress in developing bomedemstat as a potential new treatment option for patients living with this rare blood disorder. The initiation of this Phase III trial represents an important milestone in advancing innovative therapies that could improve disease control and quality of life for those impacted by essential thrombocythemia.

Read more: https://lnkd.in/eiHZwezF